Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy
- PMID: 16504615
- DOI: 10.1016/j.ahj.2005.03.049
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy
Abstract
A low level of high-density lipoprotein cholesterol (HDL-C) is a major risk factor for cardiovascular disease; however, patients with low levels of HDL-C without raised low-density lipoprotein cholesterol (LDL-C) levels are not currently eligible for lipid-lowering therapy. Many individuals with low levels of HDL-C have a combination of cardiovascular risk factors that include high LDL particle concentrations. Lowering LDL particle concentration and its surrogate measure, LDL-C, is an important approach to reducing cardiovascular risk. Statins are the most effective agents for lowering levels of LDL and can significantly increase levels of HDL-C. Extending statin therapy to patients with low levels of HDL-C but with LDL-C levels below target may have benefits for cardiovascular disease reduction in these patients.
Similar articles
-
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94. doi: 10.1016/j.amjopharm.2007.10.002. Am J Geriatr Pharmacother. 2007. PMID: 17996658
-
LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.Curr Med Res Opin. 2005 Nov;21(11):1865-74. doi: 10.1185/030079905X74952. Curr Med Res Opin. 2005. PMID: 16307708 Clinical Trial.
-
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Heart. 2008. PMID: 18480348 Review.
-
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.Eur Heart J. 2004 May;25(9):771-7. doi: 10.1016/j.ehj.2004.03.013. Eur Heart J. 2004. PMID: 15120888 Clinical Trial.
-
Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S72-5. doi: 10.1053/ajkd.2003.50089. Am J Kidney Dis. 2003. PMID: 12612957 Review.
Cited by
-
Preventing a Cardiovascular Disease Epidemic among Indigenous Populations through Lifestyle Changes.Int J Prev Med. 2012 Apr;3(4):230-40. Int J Prev Med. 2012. PMID: 22624079 Free PMC article.
-
Off-target toxicity: risks associated with adrenal corticoid activation in ILLUMINATE.Curr Atheroscler Rep. 2008 Jun;10(3):227-9. doi: 10.1007/s11883-008-0035-x. Curr Atheroscler Rep. 2008. PMID: 18489850 No abstract available.
-
Preexisting statin therapy is not associated with reduced acute kidney injury following cardiac surgery: a retrospective analysis.Front Pharmacol. 2025 May 30;16:1613681. doi: 10.3389/fphar.2025.1613681. eCollection 2025. Front Pharmacol. 2025. PMID: 40520192 Free PMC article. Review.
-
High-density Lipoprotein Cholesterol Is Negatively Correlated with Bone Mineral Density and Has Potential Predictive Value for Bone Loss.Lipids Health Dis. 2021 Jul 25;20(1):75. doi: 10.1186/s12944-021-01497-7. Lipids Health Dis. 2021. PMID: 34304735 Free PMC article.
-
Cardiovascular complications in HIV management: past, present, and future.J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):54-64. doi: 10.1097/QAI.0b013e31818ceaa4. J Acquir Immune Defic Syndr. 2009. PMID: 19295335 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical